ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings is well positioned in the orthopedic market, with a leading market share in the U.S., Europe, and Japan after the strategic acquisitions of Centerpulse and Biomet. While roughly two-thirds of revenue is derived from sales of large joints, the company also has a diverse portfolio including dental and spine products, as well as surgical supplies and instruments. However, there are potential challenges such as pricing pressures and the risk of competition from new products and market entrants, particularly in international markets. Despite these risks, the company's strong focus on its core orthopedic business and its recent positive quarterly results make it an attractive option for investors.

Zimmer Biomet Holdings is facing multiple challenges including slower revenue and EPS growth, margin pressures, and executional hurdles with their transition to direct salesforce. Their recent performance was boosted by a one-time tariff refund and their guidance for the rest of 2026 is conservative. While their strategic initiatives and product launches show potential for long-term success, the company's near-term outlook is uncertain, leading to a negative outlook. Additionally, the current valuation of the stock may not be justified given the company's slower growth compared to its peers.